Drug updated on 4/17/2024
| Dosage Form | Injection (subcutaneous; 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in single-dose pen) |
| Drug Class | Glucose-dependent insulinotropic polypeptides (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Summary
- Tirzepatide (Mounjaro) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- A total of 17 systematic reviews/meta-analyses focused on the efficacy and safety of tirzepatide compared to other glucagon-like peptide-1 receptor agonists (GLP-1RAs) and various glucose-lowering treatments for adults with type 2 diabetes mellitus.
- One study highlighted that tirzepatide was particularly effective in Japanese patients with type 2 diabetes, showing superior reductions in HbA1c levels and body weight compared to subcutaneous semaglutide and other GLP-1RAs.
- Across multiple studies, it was noted that tirzepatide significantly reduced HbA1c levels and body weight when compared to both oral or subcutaneous semaglutides as well as other GLP-1RAs. The most significant reduction was observed at a dose of 15 mg.
- Tirzepatide also showed superiority over basal insulin by offering more significant reductions in HbA1c levels along with fewer instances of hypoglycemia.
- The drug's efficacy demonstrated a dose-response relationship; higher doses (10mg and 15mg) showed greater effectiveness than the lower one (5mg).
- Tirzepatide has been associated with a higher incidence rate of gastrointestinal symptoms such as nausea, vomiting, decreased appetite, dyspepsia, constipation, and diarrhea when compared to placebo or any other GLP-1RAs. These side effects have shown dependence on dosage.
- No increase in pancreatitis risk has been observed. However, a potential increased risk for gallbladder or biliary diseases requires attention during clinical practice.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Mounjaro (tirzepatide) Prescribing Information. | 2023 | Lilly USA LLC, Indianapolis, IN |